Clinical trials: Diabetes Prevention
Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD)
Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention
The study will explore the impact of photobiomodulation (PBM), pulsating at frequencies of red (660nm) and near-infrared (810nm)(NIR), concurrent with a ketogenic dietary protocol (serum ketones @ .5 - 2.0 mmol/L) to mediate…
- Conditions
- Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
- Trial name
- NCT03859245
- Testing
- Photobiomodulation, Ketogenic diet
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristlecone Health, Inc.
Peripheral Arterial Disease (PAD), Moderate Risk for Cardiovascular Disease (CVD)
Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary Prevention
Non interventional study aimed to establish the prevalence of lower extremity peripheral arterial disease (PAD), defined as an ankle-brachial index (ABI) not above 0.90 in subjects with a moderate risk of cardiovascular disease…
- Trial name
- PANDORA (NCT00689377)
- Where
- 331 sites in Belgium, France and 4 more
- Volunteers
- 9,000 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.
- Trial name
- THEMIS (NCT01991795)
- Testing
- Ticagrelor 60 mg
- Where
- 1,237 sites in United States, Argentina and 41 more
- Volunteers
- 19,271 people
- Sponsor
- AstraZeneca
Overweight, Prediabetic State
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and…
- Conditions
- Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
- Trial name
- ATTAIN-NOW (NCT07794579)
- Testing
- Orforglipron
- Where
- 180 sites in United States, Argentina and 10 more
- Volunteers
- 2,001 people
- Sponsor
- Eli Lilly and Company
Major Coronary Event, Cerebrovascular Accident
CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events
A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy…
- Conditions
- Major Coronary Event, Cerebrovascular Accident, Coronary Artery Bypass Graft, Angina, Unstable
- Trial name
- CARDS (NCT00327418)
- Testing
- Atorvastatin
- Where
- 135 sites in United Kingdom
- Volunteers
- 2,800 people
- Sponsor
- Pfizer
Prediabetic
Efficacy and Safety of DLBS3233 in Prediabetic Patients
This is a 2-arm, prospective, double blind, randomized, and controlled clinical study for 12 weeks of therapy to investigate clinical efficacy and safety of DLBS3233.
- Trial name
- DIPPER-DM (NCT01531933)
- Testing
- DLBS3233
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Dexa Medica Group
Type 1 Diabetes
Prevention of Severe Hypoglycaemia With Hypo-Safe Hypoglycaemia Alarm Device
Hypoglycaemia is the most common acute complication in insulin-treated diabetes. The fear of hypoglycaemia discourages diabetic subjects from the attempt to maintain tight glycemic control, which in turn leads to increased…
- Trial name
- NCT01178476
- Testing
- Hyposafe Hypoglycaemia alarm device
- Where
- Denmark
- Sponsor
- UNEEG Medical A/S
Type 1 Diabetes
Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes
A premarket, international multicenter, prospective, open label, adaptive, randomized controlled study. The aim is to evaluate the efficacy of sensor augmented pump therapy with MiniMed™640G and SmartGuard™in preventing…
- Trial name
- SMILE (NCT02733991)
- Testing
- MiniMed™640G and Suspend before low, MiniMed™640G
- Where
- 14 sites in France, Italy and 2 more
- Volunteers
- 153 people
- Sponsor
- Medtronic MiniMed, Inc.
PreDiabetes
Intestinimonas for Prevention of Type 2 Diabetes Mellitus
The study aims to assess the effects of a microbiota-based product containing Intestinimonas in adults with pre-diabetes. The purpose is to determine the safety and efficacy of the microbiota-based product on insulin sensitivity…
- Trial name
- NCT04495972
- Testing
- Intestinimonas-capsules
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Caelus Pharmaceuticals BV
Diabetes Mellitus, Type 2
Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular…
- Trial name
- Navigator (NCT00097786)
- Testing
- Valsartan 160 mg + nateglinide 60 mg
- Where
- 38 sites in United States, Argentina and 36 more
- Volunteers
- 9,306 people
- Sponsor
- Novartis Pharmaceuticals
Metabolic Syndrome, Obesity & Overweight
Evaluating the SWW Method Dietary Intervention for HbA1c and Weight Management as a Preventative Intervention in Women
This study evaluated the SWW Method®, a 12-week dietary and lifestyle intervention based on the carbohydrate-insulin model, in a healthy cohort of women aged 35-75.
- Conditions
- Metabolic Syndrome, Obesity & Overweight, Blood Glucose Monitoring, Type 2 Diabetes Prevention
- Trial name
- NCT07463417
- Testing
- SWW Method® Dietary and Lifestyle Intervention
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Sarah Wragge Wellness
Cardiovascular Disease
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
The aim of this study was to estimate the number of United States (US) adults with and without prior atherosclerotic cardiovascular disease (ASCVD) and diabetes who may be eligible for inclisiran based on US National Health and…
- Trial name
- NCT07214857
- Where
- United States
- Volunteers
- 1,385 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2, PreDiabetes
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease.
- Conditions
- Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
- Trial name
- TRANSFORM (NCT06112418)
- Testing
- The Cleerly CAD Staging System
- Where
- 125 sites in United States
- Volunteers
- 7,500 people, healthy volunteers welcome
- Sponsor
- Cleerly, Inc.
Prediabetic State
Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes
Primary objective: To evaluate the effect of long-term administration of Rimonabant on the time of progression to type 2 diabetes in patients with prediabetes (i.e.
- Trial name
- RAPSODI (NCT00325650)
- Testing
- Rimonabant
- Where
- United States
- Volunteers
- 2,420 people
- Sponsor
- Sanofi
Hyperlipidemias, Atherosclerosis
Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy.
- Conditions
- Hyperlipidemias, Atherosclerosis, Coronary Heart Disease, Carotid Stenosis
- Trial name
- NCT00536965
- Where
- Austria
- Volunteers
- 951 people
- Sponsor
- AstraZeneca
Prediabetes, Overweight
Evaluation of Prevent in Underserved Populations
The goal of this study is to evaluate an online Diabetes Prevention Program adapted for patients with prediabetes in safety net health care settings.
- Conditions
- Prediabetes, Overweight, Obesity
- Trial name
- PUP (NCT02664064)
- Testing
- Prevent
- Where
- 3 sites in United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Omada Health, Inc.
Identification of Infants at Risk for Type 1 Diabetes
Freder1k-Study - Testing Infants for Type 1 Diabetes Risk
The Freder1k-Study will identify infants who have a high genetic risk of type 1 diabetes.
- Trial name
- NCT03316261
- Where
- Germany
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Helmholtz Zentrum München
Exposure to Hepatitis B Virus
Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine
There is a need for more effective and better-tolerated hepatitis B vaccines for low responder high-risk populations including patients with renal impairment and/or diabetes mellitus and those aged over 40 years.
- Trial name
- NCT01951677
- Testing
- HBsAg, PreS HBsAg, Advax-1(TM)
- Where
- Australia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Diabetic Foot Ulcers
Hyperspectral Imaging to Assess and Predict Diabetic Foot Ulcers
This study is designed to test a prototype imaging instrument that relies on Medical HyperSpectral Imaging (MHSI) technology for the assessment and prediction of diabetic foot ulceration and wound healing.
- Trial name
- NCT00617916
- Where
- 3 sites in United States
- Volunteers
- 256 people
- Sponsor
- HyperMed
PreDiabetes
Prevention of Microvascular Complications in Prediabetes e-PREDICE Study
Background: A significant proportion of pre-diabetics, show macro and micro vascular complications associated with hyperglycaemia.
- Trial name
- ePREDICE (NCT03222765)
- Where
- Spain
- Volunteers
- 1,000 people
- Sponsor
- Evidem Consultores SL